Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Ibio Inc (IBIO)

Ibio Inc (IBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 37,154
  • Shares Outstanding, K 218,166
  • Annual Sales, $ 2,370 K
  • Annual Income, $ -23,210 K
  • 60-Month Beta -4.23
  • Price/Sales 13.18
  • Price/Cash Flow N/A
  • Price/Book 0.50
Trade IBIO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.20
  • Most Recent Earnings -0.06 on 05/12/22
  • Next Earnings Date 10/03/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 327.96% ( -70.98%)
  • Historical Volatility 198.10%
  • IV Percentile 71%
  • IV Rank 28.54%
  • IV High 1,002.36% on 09/12/22
  • IV Low 58.67% on 06/13/22
  • Put/Call Vol Ratio 0.01
  • Today's Volume 225
  • Volume Avg (30-Day) 545
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 33,318
  • Open Int (30-Day) 36,188

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.05
  • Growth Rate Est. (year over year) +1,998,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1530 +8.30%
on 10/03/22
0.6604 -74.91%
on 09/16/22
-0.1193 (-41.86%)
since 09/02/22
3-Month
0.1530 +8.30%
on 10/03/22
0.6604 -74.91%
on 09/16/22
-0.0943 (-36.27%)
since 07/01/22
52-Week
0.1530 +8.30%
on 10/03/22
1.0300 -83.91%
on 10/05/21
-0.8743 (-84.07%)
since 10/01/21

Most Recent Stories

More News
Pre-Market Brief: Stocks Plunge On Mounting Recession Risks

December S&P 500 futures (ESZ22) are trending down -0.68% this morning after the Dow Jones Industrial Average and S&P 500 index continued to fall deeper into bear-market territory as investors digested...

ESZ22 : 3,713.00 (+0.62%)
BIIB : 264.30 (-1.01%)
RUM : 12.29 (+0.33%)
MNMD : 3.31 (-5.43%)
SAND : 5.27 (+1.93%)
IBIO : 0.1657 (-2.70%)
3 Biotech Penny Stocks to Avoid

The biotech industry thrived during the pandemic. However, that seems to be fading as the pandemic situation has relaxed. And given the inherent volatility of penny stocks, iBio (IBIO), VistaGen Therapeutics...

IBIO : 0.1657 (-2.70%)
TMBR : 0.0949 (-20.92%)
VTGN : 0.1605 (+5.52%)
iBio (IBIO) Q3 2022 Earnings Call Transcript

IBIO earnings call for the period ending March 31, 2022.

IBIO : 0.1657 (-2.70%)
iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update

BRYAN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and...

IBIO : 0.1657 (-2.70%)
iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022

BRYAN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and...

IBIO : 0.1657 (-2.70%)
iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference

BRYAN, Texas, March 11, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and...

IBIO : 0.1657 (-2.70%)
Pipeline Therapeutics Appoints Eef Schimmelpennink to its Board of Directors

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, today announced the appointment of...

PFNX : 12.75 (-0.08%)
IBIO : 0.1657 (-2.70%)
iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update

BRYAN, Texas, Feb. 14, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and...

IBIO : 0.1657 (-2.70%)
iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022

BRYAN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and...

IBIO : 0.1657 (-2.70%)
iBio Announces Participation in the H.C. Wainwright BioConnect Conference

BRYAN, Texas, Jan. 04, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and...

IBIO : 0.1657 (-2.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Ibio Inc., formerly known as iBioPharma Inc., is a biopharmaceutical company that primarily focuses on developing vaccines and therapeutic proteins based upon its plant-based iBioLaunch platform technology. The Company's hydroponically grown green plants can be used for the development and manufacture...

See More

Key Turning Points

3rd Resistance Point 0.1980
2nd Resistance Point 0.1864
1st Resistance Point 0.1761
Last Price 0.1657
1st Support Level 0.1542
2nd Support Level 0.1426
3rd Support Level 0.1323

See More

52-Week High 1.0300
Fibonacci 61.8% 0.6950
Fibonacci 50% 0.5915
Fibonacci 38.2% 0.4880
Last Price 0.1657
52-Week Low 0.1530

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar